Opus Genetics, a Durham-based company developing drugs to treat retinal diseases has raised an additional $4.5 million from investors. Here’s how the CEO plans to invest the money.
Read More
NCBiotech Writer Barry Teater takes an inside look at this week’s deal by RTP startup Opus Genetics to step up the battle against blindness.
Read More
Triangle startup Opus Genetics is adding two potential treatments targeting retinal disease in a deal that cost it cash up front and an ownership stake.
Read More
Research Triangle-based gene therapy company Opus Genetics is appointing its acting CEO to the permanent role, the company announced this week.
Read More
Opus Genetics, a gene therapy startup based in Research Triangle Park, has brought in an industry veteran to lead development.
Read More
Triangle-based Opus Genetics has a new relationship with National Resilience, Inc., and the agreement includes quality control testing and manufacturing.
Read More
Impact investing is on the rise, and local pharmaceutical industry insiders say it’s already paying off. Here’s a look at a growing trend in the search for cures.
Read More
RALEIGH – Opus Genetics recently announced it would open its third preclinical trial, just a few months after the company formed with a $19 million seed financing round led by the venture capital arm of the Foundation Fighting Blindness, the RD Fund. The company, founded by the RD Fund, also...
Read More
Raleigh-based Opus Genetics will launch a third preclinical trial, the company announced this week., as it continues rapid development after raising $19 million in funding.
Read More
